Transvaginal NOSES Versus Conventional Laparoscopic Surgery for Right Hemicolectomy
Recruiting now · Not applicable
Conditions studied: Colon Cancer
In brief
It is controversial that totally laparoscopic right hemicolectomy with transvaginal natural orifice specimen extraction (NOSES VIIIA) can provide non-inferior oncological outcomes compared to conventional laparoscopic surgery with mini-laparotomy in the treatment of right colon cancer. We aim to carry out a multicenter, open-lable, parallel, non-inferiority, phase III, randomized controlled clinical trial, which enrolls 356 female patients with cT1-3NxM0 right colon adenocarcinoma. They are randomly assigned to the experimental group (NOSES VIIIA) or the control group (laparoscopic surgery with mini-laparotomy) in a 1:1 ratio. Perioperative indicators, pathological results, quality of life and cosmetic evaluation will be compared between the two groups. Then, a three-year follow-up of these patients will provide evidence for long-term oncological outcomes of NOSES VIIIA.
Key facts
- Study ID
- NCT05495048
- Run by
- Shanghai Minimally Invasive Surgery Center
- People needed
- 356
- Starts
- 2023-07-01
- Expected to finish
- 2028-12-31
- Last updated by the study team
- 2024-02-26
Who can join
Age: 18 and older, up to 75. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- volunteer to participate and the informed consent signed;
- 18-75 years;
- female who have given birth;
- pathologically confirmed adenocarcinoma/high-grade intraepithelial neoplasia by preoperative colonoscopy and biopsy;
- preoperative CT or MRI indicates that the tumor diameter is no more than 5.0 cm;
- preoperative staging cT1-3NanyM0
- body mass index <30 kg/m2;
- willing to undergo laparoscopic right hemicolectomy
You may not qualify if…
- contraindications for laparoscopic surgery;
- emergency surgery due to acute intestinal obstruction, perforation or bleeding;
- distant metastasis;
- multiple colorectal cancer;
- has received preoperative chemoradiotherapy;
- with a history of other malignant tumors;
- unwilling to sign the informed consent or receive follow-up according to the study protocol.
Where it is running
- Ruijin Hospital — Shanghai, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.